[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:gtpase-kras":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","GTPase KRas",49,[8,16,23,29,35,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,150,156,162,168,174,180,186,192,197,203,209,215,220,226,232,238,244,250,256,262,268,274,280,287,294,300],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06619587","A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.509157Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05410145","A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",[20],"Phase 1\u002FPhase 2","2026-08-26T02:17:03.534765Z","2026-05-05T02:43:29.047352Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07456046","A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.",[12],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:29.026378Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06096974","Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS",[12],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.566526Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT07172919","A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation",[39],"Phase 2","2026-08-26T02:15:01.639696Z","2026-05-05T02:43:28.558810Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07030959","Study of AUBE00 in Patients With Solid Tumors",[12],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:28.191330Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07204340","TLN-372 in Advanced KRAS Mutant Solid Tumors",[12],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:27.444808Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06797336","A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors",[12],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:27.435980Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT07021898","A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.",[12],"2026-08-26T02:19:21.761002Z","2026-05-05T02:43:27.258450Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06720987","A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",[12],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.252443Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07247110","A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:26.975571Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06162221","Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",[20],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:26.935632Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05661201","NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors",[12],"2026-08-26T02:17:42.501124Z","2026-05-05T02:43:26.768897Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT05382559","A Study of ASP3082 in Adults With Advanced Solid Tumors",[12],"2026-08-26T02:16:46.951087Z","2026-07-05T05:32:16.801787Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06917079","BBO-11818 in Adult Subjects With KRAS Mutant Cancer",[12],"2026-08-26T02:18:35.425468Z","2026-07-05T05:32:16.701709Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07629960","A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations",[20],"2026-08-26T02:15:38.131683Z","2026-06-06T00:48:49.532877Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07563738","A 2-part Phase 1\u002F2 Open-label Trial on ODM-212",[20],"2026-08-26T02:15:26.669629Z","2026-05-13T02:55:06.727821Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07209111","A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)",[39],"2026-08-26T02:16:29.226604Z","2026-05-05T02:43:29.664838Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT06835569","A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",[12],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:29.166414Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT07094113","AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.028170Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT05379985","Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",[20],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:29.015195Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06179160","A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",[12],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:28.983627Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06625775","Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:28.969601Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06244771","A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors",[20],"2026-08-26T02:19:12.219640Z","2026-05-05T02:43:28.733888Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT07020221","A Phase 1\u002F2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",[20],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.705701Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT07094204","A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",[12],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.482220Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT06128551","Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors",[20],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:28.404529Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT06586515","MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.316565Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT06973564","JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration",[20],"2026-08-26T02:16:38.053590Z","2026-05-05T02:43:27.913684Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT07349537","Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors",[12],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:27.730554Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":118,"content_modified":196},"NCT07207707","A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies",[12],"2026-05-05T02:43:27.668162Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT05067283","A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)",[12],"2026-08-26T02:16:12.203827Z","2026-05-05T02:43:27.569866Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT06040541","Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors",[12],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:27.518589Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.481677Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":21,"content_modified":219},"NCT06385925","A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation",[20],"2026-05-05T02:43:27.287481Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT07223047","A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",[20],"2026-08-26T02:18:55.570428Z","2026-05-05T02:35:31.728570Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT07252479","Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",[12],"2026-08-26T02:16:01.910993Z","2026-06-16T05:54:07.937487Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT06764771","A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",[12],"2026-08-26T02:15:10.362237Z","2026-06-04T01:30:07.895587Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT06026410","KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",[12],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.472498Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT07148128","Phase 1\u002F2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.",[20],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:28.963256Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":254,"content_modified":255},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[12],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":260,"content_modified":261},"NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients",[20],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:28.129328Z",{"nct_id":263,"title":264,"phases":265,"status":13,"updated_at":266,"content_modified":267},"NCT07064018","Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:35:31.867839Z",{"nct_id":269,"title":270,"phases":271,"status":13,"updated_at":272,"content_modified":273},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[20],"2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z",{"nct_id":275,"title":276,"phases":277,"status":13,"updated_at":278,"content_modified":279},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[12],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.906567Z",{"nct_id":281,"title":282,"phases":283,"status":284,"updated_at":285,"content_modified":286},"NCT07650357","A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)",[12],"NOT_YET_RECRUITING","2026-08-26T02:18:46.948970Z","2026-06-17T02:29:30.058689Z",{"nct_id":288,"title":289,"phases":290,"status":291,"updated_at":292,"content_modified":293},"NCT05853367","Study of MK-0472 in Participants With Advanced\u002FMetastatic Solid Tumors (MK-0472-001)",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:12:04.122101Z","2026-05-05T02:43:28.853128Z",{"nct_id":295,"title":296,"phases":297,"status":291,"updated_at":298,"content_modified":299},"NCT07023731","A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation",[20],"2026-08-03T03:16:06.901903Z","2026-05-05T02:43:26.962034Z",{"nct_id":301,"title":302,"phases":303,"status":291,"updated_at":304,"content_modified":305},"NCT06447662","A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",[12],"2026-08-03T03:38:39.261584Z","2026-05-05T02:43:29.038880Z"]